Citadel Advisors LLC Invests $874,000 in Eidos Therapeutics Inc (EIDX) Stock

Citadel Advisors LLC acquired a new position in shares of Eidos Therapeutics Inc (NASDAQ:EIDX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 42,960 shares of the company’s stock, valued at approximately $874,000. Citadel Advisors LLC owned 0.12% of Eidos Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Board of Trustees of The Leland Stanford Junior University bought a new position in Eidos Therapeutics during the 2nd quarter worth $3,642,000. Dean Capital Investments Management LLC bought a new position in shares of Eidos Therapeutics in the 2nd quarter valued at $528,000. Tiverton Asset Management LLC bought a new position in shares of Eidos Therapeutics in the 2nd quarter valued at $163,000. BlackRock Inc. bought a new position in shares of Eidos Therapeutics in the 2nd quarter valued at $3,051,000. Finally, Janus Henderson Group PLC bought a new position in shares of Eidos Therapeutics in the 2nd quarter valued at $6,511,000. Hedge funds and other institutional investors own 22.93% of the company’s stock.

Shares of EIDX opened at $13.07 on Friday. Eidos Therapeutics Inc has a 52-week low of $11.39 and a 52-week high of $24.75.



Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($1.15). analysts anticipate that Eidos Therapeutics Inc will post -2.09 EPS for the current year.

In other news, CEO Neil Kumar acquired 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, June 22nd. The shares were bought at an average price of $17.00 per share, with a total value of $17,000,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Rajeev M. Shah acquired 1,058,824 shares of the business’s stock in a transaction that occurred on Friday, June 22nd. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The disclosure for this purchase can be found here.

EIDX has been the topic of several recent analyst reports. JPMorgan Chase & Co. initiated coverage on Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $36.00 price target on the stock. Bank of America initiated coverage on Eidos Therapeutics in a research note on Monday, July 16th. They issued a “neutral” rating and a $24.00 price target on the stock. Finally, Barclays initiated coverage on Eidos Therapeutics in a research note on Monday, July 16th. They issued an “overweight” rating and a $32.00 price target on the stock.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Featured Story: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding EIDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eidos Therapeutics Inc (NASDAQ:EIDX).

Institutional Ownership by Quarter for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply